Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study.
Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study.
复制标题
DOI：
10.1111/jdi.12851
复制
发表时间：
2019-01
影响因子：
3.2
通讯作者：
Fukuda M
中科院分区：
文献类型：
--
作者：
Sasaki T;Sugawara M;Fukuda M
目前尚不清楚钠-葡萄糖协同转运蛋白 2 (SGLT2) 抑制剂治疗引起的身体成分变化如何与代谢特征变化相关。我们的目的是阐明代谢特征的变化如何与身体成分的变化相关，以及 SGLT2 抑制剂治疗是否会导致肌肉减少症和骨矿物质含量 (BMC) 损失。对中度肥胖的日本 2 型糖尿病患者进行为期一年的 luseogliflozin 治疗，对他们的身体成分变化进行前瞻性观察和评估。我们分析了治疗期间个体身体成分的变化及其与其他临床变量的相关性。疗效分析组包括 43 名入组患者中的 37 名。总脂肪量在第4周及之后的治疗早期显着下降，第24周时平均下降-1.97公斤（95%置信区间-2.66至-1.28）。第24周时内脏脂肪面积显示出平均下降趋势，尽管这并不显着。个体患者内脏脂肪面积的变化与基线内脏脂肪面积的范围呈显着负相关（r = -0.399，P = 0.023）。骨骼肌质量指数在第 36 周及之后显示出显着但微小的变化。BMC 曲线仅在第 12 周显示出短暂的显着下降。在其他时间点未注意到 BMC 的显着变化。 Luseogliflozin治疗给中度肥胖的日本2型糖尿病患者的身体成分和代谢带来了有利的变化，伴随着身体脂肪的减少，以及最小的肌肉和BMC的减少。
It is unclear how changes in body composition induced by sodium–glucose cotransporter 2 (SGLT2) inhibitor treatment correlate with metabolic profile changes. We aimed to clarify how metabolic profile changes correlate with body component changes, and if SGLT2 inhibitor treatment causes sarcopenia and bone mineral content (BMC) loss. Moderately obese Japanese type 2 diabetes patients, treated with luseogliflozin for a year, were observed prospectively and evaluated for body composition changes. We analyzed the changes in the individual body components during treatment, and their correlation with other clinical variables. The efficacy analysis set comprised 37 of 43 enrolled patients. The total fat mass significantly decreased early in the treatment at and after week 4, with a mean decrease of −1.97 kg (95% confidence interval −2.66 to −1.28) at week 24. The visceral fat area at week 24 showed an average downward trend, although this was not significant. The changes in visceral fat area in individual patients showed a significant negative correlation with the extent of the baseline visceral fat area (r = −0.399, P = 0.023). The skeletal muscle mass index showed a significant but small change at and after week 36. The BMC profile showed a transient significant decrease only at week 12. No significant change in BMC was noted at other time‐points. Luseogliflozin treatment brought about favorable changes in body composition and metabolism of moderately obese Japanese type 2 diabetes patients, accompanied by body fat reduction, and minimal muscle and BMC reduction.
登录
查看更多内容
影响因子：
5.8
作者：
Bolinder, J.;Ljunggren, O.;Parikh, S.
通讯作者：
Parikh, S.
影响因子：
158.5
作者：
Neal, Bruce;Perkovic, Vlado;Matthews, David R.
通讯作者：
Matthews, David R.
影响因子：
168.9
作者：
Cefalu, William T.;Leiter, Lawrence A.;Meininger, Gary
通讯作者：
Meininger, Gary
影响因子：
3.2
作者：
Seino Y;Yabe D;Sasaki T;Fukatsu A;Imazeki H;Ochiai H;Sakai S
通讯作者：
Sakai S
影响因子：
3.2
作者：
Haneda, Masakazu;Seino, Yutaka;Samukawa, Yoshishige
通讯作者：
Samukawa, Yoshishige